March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Dr. Keith Thompson, CMO at Nuralogix, dives into virtual care, telemedicine, and advanced digital health tools for improving primary care workflows and population health. He also shares his insights into…
Mike Waldron, CEO and Co-Founder of Propel VR, discusses how virtual reality (VR) and augmented reality (AR) can be leveraged in the healthcare industry, including specific applications of VR/AR for…
Ariel Garten, Founder & Chief Evangelism Officer at Muse, explores many exciting topics such as the idea of whether art and beauty can be broken down into biological codes, the…
Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its…
Caitlin Wagner, Associate Marketing Director at Pharming, shares her expertise on innovative patient engagement strategies, including the roles of mobile apps and social media, the impact of the COVID-19 pandemic…
Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his…
Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac…
Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that…
Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work…
Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, talks about everything from his personal health journey to his…
